Medtronic PLC $MDT Shares Bought by Private Advisor Group LLC

Private Advisor Group LLC raised its holdings in Medtronic PLC (NYSE:MDT) by 44.6% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 149,559 shares of the medical technology company’s stock after purchasing an additional 46,162 shares during the quarter. Private Advisor Group LLC’s holdings in Medtronic were worth $14,244,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Norges Bank purchased a new position in shares of Medtronic during the second quarter worth $1,432,698,000. Barclays PLC raised its holdings in shares of Medtronic by 104.6% in the 3rd quarter. Barclays PLC now owns 6,831,203 shares of the medical technology company’s stock valued at $650,604,000 after buying an additional 3,492,192 shares during the period. Guinness Asset Management LTD purchased a new stake in shares of Medtronic in the 3rd quarter valued at $275,556,000. Vanguard Group Inc. lifted its stake in Medtronic by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after acquiring an additional 1,895,165 shares in the last quarter. Finally, Magellan Asset Management Ltd acquired a new position in Medtronic during the 3rd quarter worth about $126,347,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $89.79 on Wednesday. The stock’s 50-day simple moving average is $98.45 and its 200-day simple moving average is $97.00. The firm has a market capitalization of $115.28 billion, a PE ratio of 25.01, a price-to-earnings-growth ratio of 2.29 and a beta of 0.71. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.87 and a current ratio of 2.54.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The firm’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be issued a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.2%. Medtronic’s dividend payout ratio is presently 79.11%.

Insider Activity at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.26% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have weighed in on MDT. Truist Financial dropped their target price on Medtronic from $107.00 to $103.00 and set a “hold” rating for the company in a research report on Wednesday, February 18th. TD Cowen reissued a “buy” rating on shares of Medtronic in a research report on Friday, November 14th. Robert W. Baird lowered their price objective on shares of Medtronic from $103.00 to $100.00 and set a “neutral” rating for the company in a research note on Wednesday, February 18th. JPMorgan Chase & Co. dropped their price objective on shares of Medtronic from $105.00 to $100.00 and set a “neutral” rating for the company in a report on Wednesday, February 18th. Finally, The Goldman Sachs Group set a $111.00 target price on shares of Medtronic and gave the stock a “neutral” rating in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $110.74.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic agreed to acquire Scientia Vascular for $550 million to bolster its neurovascular access and therapeutic portfolio — a strategic tuck‑in that expands “time‑is‑brain” capabilities and complements existing neurovascular product lines. Medtronic to acquire Scientia Vascular, marrying access and therapeutic portfolios for neurovascular care
• Neutral Sentiment: Analyst coverage is active — a Benzinga deep dive summarizes 10 analyst ratings showing mixed views on MDT’s valuation and growth prospects; this keeps price target dispersion and investor debate elevated. Deep Dive Into Medtronic Stock: Analyst Perspectives (10 Ratings)
• Neutral Sentiment: Management commentary at the Barclays Healthcare Conference (transcript) reaffirmed strategy and longer‑term objectives; investors will be parsing any incremental detail on margin drivers, product cadence and the FY26 guide. Medtronic plc (MDT) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
• Neutral Sentiment: Leadership change: Sean Haag named president of Medtronic’s ENT business — an operational move that matters for execution in ENT but is not expected to materially alter near‑term financials. Medtronic names Sean Haag president of ENT business
• Negative Sentiment: Competitive pressure from NeuroPace (NPCE) — recent coverage highlights product and reimbursement tailwinds for NeuroPace’s RNS system that could accelerate adoption in neuromodulation and pose longer‑term share/price pressure in adjacent markets. Investors view stronger competitor momentum as a headwind for Medtronic’s neuromodulation ambitions. NeuroPace’s Seizure ID and New Indication Could Expand RNS Demand
• Negative Sentiment: Macro/market volatility (rising VIX) is weighing on large‑cap medical device names, increasing downside risk from sector‑wide flows and multiple compression rather than company‑specific fundamentals. When Fear Spikes, These 5 Quiet, Overlooked Stocks Keep Delivering

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).